ATTO NASDAQ
Attovia Therapeutics, Inc.
1W: -0.1%
1M: -21.9%
3M: +2843.8%
YTD: -36.6%
1Y: +226.6%
3Y: +56.0%
5Y: -61.3%
$14.40
+0.53 (+3.78%)
Weekly Expected Move ±8.8%
$11
$13
$14
$15
$16
Credit Risk of going bust: not rated Debt: 0.7% of company value Bonds: none of note held by US funds details ▾
Not rated: insufficient price history.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$52.4M
Congress—
ETF Holdings—
Key Statistics
Market Cap$633.6M
52W Range12.94-28
Volume224,593
Avg Volume446,019
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
1091 Industrial Rd, Ste 310
San Carlos, CA 94070
US
San Carlos, CA 94070
US
About Attovia Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Latest News
Attovia Therapeutics, Inc. (NASDAQ:ATTO) Stock Has Consensus Price Target of $42.20 According to Brokerages
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
Attovia Therapeutics, Inc.’s (NASDAQ:ATTO) Quiet Period To End on September 14th
Analysts Offer Insights on NA Companies: Fastenal Company (FAST) and Attovia Therapeutics, Inc. (ATTO) - theglobeandmail.com
Attovia Therapeutics to Participate in Upcoming Citi and Morgan Stanley Investor Conferences - Quiver Quantitative
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| WALSH COLIN | C-Conversion | 1,957,134 | — | 2026-08-06 |
| WALSH COLIN | C-Conversion | 478,498 | — | 2026-08-06 |
| WALSH COLIN | P-Purchase | 500,000 | $17.00 | 2026-08-06 |
| WALSH COLIN | C-Conversion | 18,181,830 | — | 2026-08-06 |
| WALSH COLIN | C-Conversion | 4,445,275 | — | 2026-08-06 |